Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2684 • ACR Convergence 2025
Multimodal Analysis Revealed Altered Brain Connectivity Patterns and Neuroinflammatory Processes in the Background of Difficult-To-Treat Rheumatoid Arthritis
Lilla Gunkl-Tóth¹, Gergely Orsi², Noémi Császár-Nagy³, Lili Duzsik⁴, Gábor Mátay⁴, Gábor Kumánovics⁵, Gábor Sütő², Krisztina Csókási², Szabolcs Takács⁶, Zoltán Vidnyánszky⁷, József Kun², Krisztina Takács-Lovász², Gellért Karvaly⁸, Róbert Farkas⁸, Anett Pintér⁸, Panna Királyhidi⁸, György Nagy⁸ and Zsuzsanna Helyes², ¹Semmelweis University, Budapest, Budapest, Hungary, ²University of Pécs, Pécs, Hungary, ³National University of Public Services, Budapests, Hungary, ⁴Psychosomatic Outpatient Clinic, Budapest, Hungary, ⁵University of Pecs, Pecs, Hungary, ⁶Károli Gáspár University, Budapest, Hungary, ⁷Brain Imaging Centre, Research Centre for Natural Sciences, Budapest, Hungary, ⁸Semmelweis University, Budapest, Hungary
Background/Purpose: Despite advances in rheumatoid arthritis (RA) treatment, 5–20% of patients experience persistent symptoms, particularly pain, and are classified as difficult-to-treat (D2T). Factors such as…
Abstract Number: 2612 • ACR Convergence 2025
Automated, Artificial Intelligence-supported Sonographic Examination of the Hands for the Detection and Quantification of Arthritis and Osteoarthritis in the Hand and Finger Joints in Outpatient Rheumatology Care
Oliver Sander¹, Lea Ormeloh¹, Laura Grünkewitz¹, Martin Gallmann¹, Benedict Blümel¹, Rishi Adhikari¹, Hasan Acar¹, Gamal Chehab¹, Jörg Distler² and Jutta Richter³, ¹Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, ²University Hospital Duesseldorf and HHU, Duesseldorf, Germany, ³Clinic for Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Duesseldorf, Germany, Düsseldorf, Germany
Background/Purpose: The integration of artificial intelligence (AI) in combination with robotics into clinical diagnostics has the potential to increase precision and efficiency and relieve increasingly…
Abstract Number: 2285 • ACR Convergence 2025
Synovium-on-a-chip – Development of a Humanized Rheumatoid Arthritis Model that Mimics Disease and Patient Biological Heterogeneity
Theresa Wampler Muskardin¹, Ruiqi Chen², Yeji Lee³, Azka Ali³, Andrra Nimoni³, Christele Felix³, Hattie Heiland³, Romy Kallas³, Daniel Ramirez⁴, David Mayman³, Timothy Niewold⁵ and Weiqiang Chen⁶, ¹Hospital for Special Surgery and Weill Cornell Medicine, New York, NY, ²New York University - Tandon School of Engineering, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, New York, New York, ⁶New York University, Tandon School of Engineering, New York, NY
Background/Purpose: In rheumatoid arthritis (RA), reasons for treatment resistance and alternate strategies that would be more effective in treatment-resistant patients remain unknown. Accurate methodology to…
Abstract Number: 2267 • ACR Convergence 2025
Impact of Baseline Cardiovascular Risk Factors Comorbidities on an Adalimumab Biosimilar Efficacy, Quality of Life and Safety In Patients with Patients with Moderately to Severely Active Rheumatoid Arthritis: Results from the AURIEL-RA study
Chris Edwards¹, Janet Pope², Joelle Monnet³ and Maria Romanova Michailidi⁴, ¹University Hospital Southampton, Southampton, United Kingdom, ²University of Western Ontario, London, ON, Canada, ³Fresenius Kabi SwissBioSim, Eysins, Switzerland, ⁴University of Geneva, Eysins, Switzerland
Background/Purpose: RA has been associated with an increase risk of cardiovascular morbidity and mortality1. The present analysis was performed to assess the efficacy (on ACR…
Abstract Number: 2251 • ACR Convergence 2025
Dual Diagnoses, Diminished Survival: Association between rheumatoid arthritis and survival among older adults with lung cancer
Michelle Nguyen¹, Aaron Baraff², Alexandra Schmidt², Alexander Peterson², Aliyah Pabani³, Nicholas Smith¹, Shelly Gray¹, Jose Garcia⁴, Noel Weiss¹ and Namrata Singh⁵, ¹University of Washington, Seattle, WA, ²VA Puget Sound Health Care System, Seattle, WA, ³Johns Hopkins, Washington, DC, ⁴VA Puget Sound Health Care System, VA GRECC, and University of Washington, Seattle, WA, ⁵University of Washington, Bellevue, WA
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of malignancies, particularly lung cancer, relative to the general population1. However, the association between RA…
Abstract Number: 2235 • ACR Convergence 2025
Proportion of Early Rheumatoid Arthritis Patients with Improved, Stable, or Worsened Lung Function Over 1-Year: Results from a Multicenter, Prospective Cohort Study
Erica Mulcaire-Jones¹, Suiyuan Huang¹, Xiaosong Wang², Misti Paudel³, Ying Qi⁴, Grace Qian⁵, Liya Sisay Getachew⁶, Emily Kowalski⁶, Kevin Mueller⁵, Alene Saavedra⁵, Lauren O'Keeffe⁵, Natalie Davis⁷, Alison Puri⁸, Kathleen Vanni⁵, Caleb Bolden⁹, Tina Mahajan¹⁰, Marzieh Jamali¹, Pierre Antoine Juge¹¹, Tracy J. Doyle¹², Marcy Bolster¹³, Kevin Deane¹⁴, Raul San Jose Estepar⁵, George Washko⁵, Gregory McDermott⁷, Bryant England¹⁰, Jeffrey Sparks⁶ and Dinesh Khanna¹, ¹University of Michigan, Ann Arbor, MI, ²Brigham and Women's Hospital, Natick, MA, ³Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁴Brigham and Women’s Hospital, Boston, ⁵Brigham and Women's Hospital, Boston, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Brigham and Women's Hospital, Brookline, MA, ⁸Boston University, Brookline, MA, ⁹Massachusetts General Hospital, Boston, ¹⁰University of Nebraska Medical Center, Omaha, NE, ¹¹Hopital Bichat, APHP, Paris, France, ¹²Brigham and Women's Hospital, West Roxbury, MA, ¹³Massachusetts General Hospital, Concord, MA, ¹⁴University of Colorado Denver Anschutz Medical Campus, Aurora, CO
Background/Purpose: Several lung diseases are associated with rheumatoid arthritis (RA), including interstitial lung disease (ILD) and emphysema. In RA-ILD baseline lung function and decline in…
Abstract Number: 2047 • ACR Convergence 2025
Trends in Lung Transplant Listing Outcomes in Connective Tissue Disease associated Interstitial Lung Disease (CTD-ILD) Across Two Decades
Sambhawana Bhandari¹, Derek E. Byers¹ and Deepali Sen², ¹Washington University in St. Louis School of Medicine, St. Louis, ²Washington University in St Louis, Chesterfield, MO
Background/Purpose: Lung transplantation represents a potential life-extending therapy for patients with advanced CTD-ILD. This study aims to characterize lung transplant listing outcomes among CTD-ILD patients…
Abstract Number: 1927 • ACR Convergence 2025
Development of the PREVAIL model of care: Optimizing feasibility and acceptability for trial implementation
Louise Thoma¹, Joel Thompson², Jason Sharpe³, Beth Jonas⁴, Patti Katz⁵ and Kelli Allen⁶, ¹University of North Carolina, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Cary, NC, ³Flatiron Health, Durham, NC, ⁴University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵UCSF, San Rafael, CA, ⁶University of North Carolina, Durham, NC
Background/Purpose: Exercise guidance and referral to physical therapy are not consistently delivered when appropriate in rheumatology care for adults with rheumatoid arthritis (RA). The PREVAIL…
Abstract Number: 1748 • ACR Convergence 2025
Effect of Air Pollution on Disease Activity in Patients with Rheumatoid Arthritis
Sung Cheol Jung¹, Jeffrey Curtis², Seojin Yang³, Min Hyuk Lim⁴, Saram Lee⁵, Sung Ik Cho⁶, Jin Kyun Park⁷ and Eun Bong Lee⁶, ¹Seoul National University College of Medicine, Seoul, Republic of Korea, ²University of Alabama at Birmingham, Birmingham, AL, ³Seoul National University, Seoul, Republic of Korea, ⁴Ulsan National Institute of Science and Technology (UNIST), Ulsan, Republic of Korea, ⁵Seoul National University Hospital, Seoul, Republic of Korea, ⁶Seoul National University Hospital, Seoul, South Korea, ⁷Seoul National University College of Medicine, Jongno-gu, Seoul, South Korea
Background/Purpose: While air pollution has been implicated in the pathogenesis of rheumatoid arthritis (RA), its association with RA disease activity remains insufficiently investigated (1, 2).…
Abstract Number: 1675 • ACR Convergence 2025
Neuroimmune modulation in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors (TNFi)
Guillermo Valenzuela¹, Jane Box², Angela Crowley³, Joshua June⁴, Pendleton Wickersham⁵, Jeff Peterson⁶, Michael Thakor⁷, Susan Kim⁸, Tina Shah⁹, David Chernoff¹⁰ and John Tesser¹¹, ¹Integral Rheumatology & Immunology Specialists, Plantation, FL, ²DJL Clinical Research, PLLC, Charlotte, NC, ³Illinois Bone and Joint Institute - Hinsdale Orthopaedics, Hinsdale, IL, ⁴Great Lakes Center of Rheumatology, Lansing, MI, ⁵Arthritis Associates PA, San Antonio, TX, ⁶Western Washington Arthritis Clinic, Seattle, WA, ⁷arthritis and rheumatology, Fort Collins, CO, ⁸Lehigh Valley Hospital Network, Allentown, PA, ⁹Kansas City Physician Partners, Kansas City, MO, ¹⁰SetPoint Medical, Sausalito, CA, ¹¹Arizona Arthritis & Rheumatology Associates, Phoenix, AZ
Background/Purpose: A substantial number of patients with rheumatoid arthritis (RA) experience treatment failure, incomplete response, or intolerance to TNFis (TNFi-IR). Neuroimmune modulation using an implantable…
Abstract Number: 1371 • ACR Convergence 2025
Effect of bDMARDs and tsDMARDS on diffuse interstitial lung disease associated with rheumatoid arthritis: systematic review and meta-analysis
Stéphane HILLIQUIN¹, Enrico VISMARA¹, Virginia BERLENGIERO² and Jérôme AVOUAC³, ¹Département de Rhumatologie, Hôpital Cochin, Assistance publique des Hôpitaux de Paris, Université Paris-Cité, Paris, France, PARIS, France, ²Rheumatoloy Department, Cochin Hospital, PARIS, France, ³Rheumatology department, Cochin hospital, Paris, France
Background/Purpose: Interstitial lung disease (ILD) is a severe complication of rheumatoid arthritis (RA), associated with increased morbidity and mortality. The pulmonary safety of biologic (bDMARDs)…
Abstract Number: 1353 • ACR Convergence 2025
Phase 3 Study of the Efficacy, Safety and Immunogenicity of the Proposed Tocilizumab Biosimilar RGB-19, Intravenously Administered to Participants With Active Rheumatoid Arthritis: 52-Week Data
Gerd Burmester¹, Hiroaki Matsuno², Ernest Choy³, Masato Okada⁴, Roshan Dias⁵, Károly Horvát-Karajz⁵, Gordana Dancer⁵, Yusuke Karibe⁶, Suguru Masuda⁶, Joachim Kiefer⁵ and Paul Emery⁷, ¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Matsuno Clinic for Rheumatic Disease, Toyama, and Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ³Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom, ⁴Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ⁵Gedeon Richter Plc, Budapest, Hungary, ⁶Mochida Pharmaceutical Co., Ltd, Tokyo, Japan, ⁷University of Leeds, Leeds, England, United Kingdom
Background/Purpose: RGB-19 is a proposed biosimilar to tocilizumab, a monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6) to its receptor. Results of a…
Abstract Number: 1336 • ACR Convergence 2025
Effectiveness of new initiators of tofacitinib and other biologic/targeted synthetic DMARDs in patients with rheumatoid arthritis
Katherine Liao¹, Chandrasekar Gopalakrishnan², Jinoos Yazdany³, Griffith Bell⁴, Suraj Mothi⁵, Genevieve Gauthier⁶, Arne Yndestad⁷ and Milena Gianfrancesco⁸, ¹Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Boston, MA, USA, Boston, MA, ²OM¹ Inc, Boston, MA, USA, Boston, ³UCSF, San Francisco, CA, ⁴Pfizer Inc, New York, NY, USA, Boston, MA, ⁵OM¹ Inc, Boston, MA, USA, Boston, MA, ⁶Pfizer Canada ULC, Kirkland, QC, Canada, Montreal, Canada, ⁷Pfizer Inc, Oslo, Norway, Oslo, Norway, ⁸Pfizer Inc, New York, NY, USA, New York, NY
Background/Purpose: Though the efficacy and safety profile of tofacitinib in RA has been established in prior trials, the effectiveness of tofacitinib in routine care settings…
Abstract Number: 1319 • ACR Convergence 2025
The Association of Rheumatoid Arthritis in Patients with Vitiligo: Systematic Review and Meta-Analysis
Nattanicha Chaisrimaneepan¹, thunyaporn Khoruamklang², Pitchaporn Yingchoncharoen³, Tulaton Sodsri⁴ and Miriam Paz³, ¹Texas Tech University Health Sciences Center, Lubbock, TX, ²²Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, bangkok, Thailand, ³Texas Tech University Health Sciences Center, Lubbock, ⁴Department of Medicine, Texas Tech University Health Sciences Center, Bangkok, Thailand
Background/Purpose: Vitiligo is associated with many autoimmune diseases, but its association with rheumatic disease has not been well-defined. Therefore, we conducted a systematic review and…
Abstract Number: 1266 • ACR Convergence 2025
Shared Decision Making in Rheumatoid Arthritis: Is RA disease activity associated with patient reported measures of shared decision making pre-SDM intervention?
Jennifer Barton¹, Joshua Baker², gabriela Schmajuk³, Madhavi Valiveti⁴, Alexandra Bennett⁵, Benjamin Morasco⁶, Allison O'Neill⁷ and Meike Niederhausen⁸, ¹VA Portland Health Care System/OHSU, Portland, OR, ²University of Pennsylvania, Philadelphia, PA, ³University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ⁴VAMC Wilmington, Wilmington, DE, ⁵Center to Improve Veteran Involvement in Care (CIVIC) and VA Portland Health Care System, Portland, OR, ⁶Center to Improve Veteran Involvement in Care, VA Portland Health Care System, Portland, OR, ⁷Center to Improve Veteran Involvement in Care, VA Portland Health Care System, Portland, OR, ⁸Oregon Health & Science University/VA Portland Health Care System, Portland, OR
Background/Purpose: Shared decision making (SDM) is outlined as the first overarching principle of the treat to target guidelines for rheumatoid arthritis (RA). The quality of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].